Schools of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Pharmacology Division, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa.
Can J Physiol Pharmacol. 2019 Dec;97(12):1169-1175. doi: 10.1139/cjpp-2019-0369. Epub 2019 Sep 6.
Diabetics are susceptible to hepatic dysfunction risks due to hyperglycaemia and insulin therapy. Conventional diabetes treatments improve glycaemic control; however, hepatic hazards associated with these agents remains a challenge. Accordingly, this study sought to investigate the effect of a dioxidovanadium complex (V) on the hepatic function in streptozotocin-induced diabetic rats. Sprague-Dawley rats (240-250 g) were divided into 4 groups ( = 6): nondiabetic control, diabetic control, insulin-treated, and vanadium complex groups. The dioxidovanadium (10, 20, and 40 mg/kg) was administered twice every 2nd day for 5 weeks and blood glucose concentration was monitored weekly. At the end of the experimental period, all the experimental groups were sacrificed, and then the lipid profile, liver superoxide dismutase, glutathione peroxidase and malondialdehyde, plasma alanine aminotransferase and aspartate aminotransferase, and C-reactive protein (CRP) concentration were measured. The administration of dioxidovanadium significantly alleviated hyperglycaemia with concomitant attenuation in oxidative stress as evidenced by reduced malondialdehyde concentrations. Furthermore, vanadium complex abolished diabetes-induced dyslipidaemia. Lastly, vanadium complex administration attenuated the increase in alanine aminotransferase, aspartate aminotransferase, and plasma C-reactive protein. These findings suggest that this metallo-compound (dioxidovanadium) may ameliorate liver dysfunction often observed in diabetes.
糖尿病患者由于高血糖和胰岛素治疗而易患肝功能障碍风险。传统的糖尿病治疗方法可以改善血糖控制；然而，这些药物相关的肝危害仍然是一个挑战。因此，本研究旨在研究二氧代钒(V)复合物对链脲佐菌素诱导的糖尿病大鼠肝功能的影响。将 Sprague-Dawley 大鼠（240-250g）分为 4 组（每组 n=6）：非糖尿病对照组、糖尿病对照组、胰岛素治疗组和钒复合物组。二氧代钒（10、20 和 40mg/kg）每 2 天给药两次，共给药 5 周，每周监测血糖浓度。在实验期末，所有实验组大鼠均被处死，然后测量血脂谱、肝超氧化物歧化酶、谷胱甘肽过氧化物酶和丙二醛、血浆丙氨酸氨基转移酶和天冬氨酸氨基转移酶以及 C 反应蛋白（CRP）浓度。二氧代钒的给药显著缓解了高血糖症，同时伴随着氧化应激的减轻，表现为丙二醛浓度降低。此外，钒复合物消除了糖尿病引起的血脂异常。最后，钒复合物的给药减轻了丙氨酸氨基转移酶、天冬氨酸氨基转移酶和血浆 C 反应蛋白的升高。这些发现表明，这种金属配合物（二氧代钒）可能改善糖尿病中常见的肝功能障碍。
